What is Zai Lab?
Zai Lab is a bio-pharmaceutical and drug discovery company established in 2014 and headquartered in Shanghai, China. The company focuses its research and development efforts on critical therapeutic areas, including oncology and autoimmune diseases. Its strategic approach involves building a robust pipeline of innovative drug candidates, aiming to address unmet medical needs in these challenging fields. The company's commitment to scientific advancement and its strategic positioning within the rapidly evolving Chinese and global healthcare markets are key to its operational strategy.
How much funding has Zai Lab raised?
Zai Lab has raised a total of $1.4B across 6 funding rounds:
Series A
$30M
Series B
$100M
Series C
$30M
Stock Offering
$150M
Share Placement
$261.3M
Stock Offering
$825M
Series A (2014): $30M with participation from Steamboat Ventures, TF Capital, Qiming Venture Partners, and Kleiner Perkins
Series B (2016): $100M led by Steamboat Ventures, TF Capital, Qiming Venture Partners, Advantech Capital, and OrbiMed
Series C (2017): $30M supported by Rock Springs Capital, Cormorant Asset Management, Vivo Capital, and OrbiMed
Stock Issuance/Offering (2017): $150M, investors not publicly disclosed
Share Placement (2020): $261.3M, investors not publicly disclosed
Stock Issuance/Offering (2020): $825M, investors not publicly disclosed
Key Investors in Zai Lab
Steamboat Ventures
Steamboat Ventures, established in 2000, focuses on empowering young companies to achieve market leadership. They invest in early to growth-stage companies across technology, media, and consumer sectors, demonstrating a commitment to creating lasting value and nurturing portfolio company growth.
Advantech Capital
Advantech Capital is a private equity fund specializing in innovation-driven growth capital within China, managing investments in TMT, E-services, and Healthcare. Formed in 2016, the firm is based in Central, Hong Kong.
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm dedicated to the healthcare sector, managing capital across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services. Their approach combines deep industry experience with investment acumen to support companies at various stages of development.
What's next for Zai Lab?
The substantial enterprise-level funding and recent strategic investment indicate Zai Lab is poised for significant expansion and advancement in its drug development pipeline. This capital infusion will likely accelerate clinical trials, enhance research capabilities, and potentially support strategic partnerships or acquisitions. The company's focus on oncology and autoimmune diseases positions it within high-growth, high-impact areas of the pharmaceutical industry, suggesting a trajectory towards bringing novel therapies to market and solidifying its position as a key player in biopharmaceutical innovation.
See full Zai Lab company page
